Substituted indole derivatives for the treatment of immunological disorders,WO 2012156936, Novartis AG, Protein kinase C theta inhibitor

TITLE-Substituted indole derivatives for the treatment of immunological disorders

Protein kinase C theta inhibitor

WO 2012156936, 22.11.2012, Novartis AG



Phosphoric acid mono-[3-[3-(4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1 -yl]-4-(7-methyl-1 H-indol-3-yl)-2,5-dioxo-2,5-dihydro-pyrrol-1 -ylmethyl] ester

1H-NMR (400 MHz, DMSO-d6): 12.10 (s, 1 H), 8.08 (d, 1 H), 7.65-7.61 (m, 2H), 7.44 (f, 1 H), 7.20 (s, 1 H), 7.06 (f, 1 H), 6.74 (d, 1 H), 6.43 (f, 1 H), 6.00 (d, 1 H), 5.29 (d, 2H), 3.87-3.01 (m, 6H), 2.37 (s, 3H), 0.97-0.62 (m, 4H).

31P-NMR (162 MHz, DMSO-d6): -6.0.

LCMS: [M+1]+ = 574.0, Rt (1) = 1.77 min., Rt (2) = 0.71 min.

Descibed is a  crystalline form of phosphoric acid mono-[3-[3-(4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1- yl]-4-(7-methyl-1 H-indol-3-yl)-2,5-dioxo-2,5-dihydro-pyrrol-1-ylmethyl] ester, especially the mono-hydrate, which preferably has an X-ray powder diffraction pattern with at least one, preferably two, more preferably three, even more preferably four, especially five, most preferably all of the following peaks at an angle of refraction 2 theta (Θ) of 9.525, 16.356, 17.091 , 18.005, 20.859, each ± 0.2

Physical properties

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter


DR ANTHONY MELVIN CRASTO Ph.D,( ICT), Worlddrugtracker, Helping millions with chemistry sites, million hits on google
This entry was posted in DRUGS and tagged . Bookmark the permalink.